FDA 483 OBSERVATION · #59 OF 1,923 MOST-CITED
Testing and release for distribution
FDA cited this observation 430 times across 388 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The firm released a batch for distribution without adequate testing to confirm it met its finished-product specifications — including identity and strength of each active ingredient and conformance to established acceptance criteria — or released despite a failure.
Why FDA writes it — Release testing is the last gate before product reaches a patient. Inadequate testing, unsuitable methods, or releasing a batch that did not meet specification means the firm cannot assure the product is what the label claims — a direct patient-safety failure.
- Test each batch for conformance to final specifications, including identity and strength of each active ingredient, prior to release.
- Use scientifically sound, validated test methods and statistically or scientifically justified sampling plans.
- Do not release any batch that fails to meet established specifications and any other relevant quality-control criteria.
- Base release on complete, reviewed records — never on a partial or overridden result.
- Release pressure leading to disposition around a failing or incomplete result rather than a documented investigation.
- Methods or sampling plans not validated or justified for the specific product, so a “pass” does not actually demonstrate conformance.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.1× the rate of the average FDA-cited firm (47.4% vs 7.8%), across 388 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the prior to release.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →